AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03943277 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational study
Description: No intervention observational study
Study NCT02804620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes
Description: The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
Study NCT01395134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromonitoring
Description: Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
Study NCT01872884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevorane Remifentanil
Description: Sevorane Remifentanil
Study NCT01872884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil
Study NCT03167905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultiva
Description: Intravenous patient controlled remifentanil (20-40mcg/ml) is only given when the patient rejects or cannot receive pethidine and entonox in non-epidural group..
Study NCT03167905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study NCT03167905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study NCT02362581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prophylaxis treatment, on demand treatment
Study NCT02672826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose tissue surgery
Description: Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
Study NCT03329508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2B001 0.6/0.75 mg
Description: Fixed low dose extended release combination capsule of pramipexole and rasagiline
Study NCT03329508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline 0.75 mg
Description: Rasagiline 0.75 mg oral extended release capsule, component
Study NCT03329508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.6 mg
Description: Pramipexole 0.6 mg oral extended release capsule, component
Study NCT03329508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Pramipexole ER
Description: Marketed Pramipexole ER titrated to optimal dose of 1.5, 3 or 4.5 mg tablet
Study NCT05026411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: T 0 Diffusion Tensor MR
Description: Magnetic resonance images has been taken from 20 individuals with eating disorders before fixed orthodontic treatment
Study NCT05026411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: T 1 Diffusion Tensor MR
Description: Magnetic resonance images will be taken from 20 individuals with eating disorders after 12 months of orthodontic treatment.
Study NCT05026411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: T 2 Diffusion Tensor MR
Description: Magnetic resonance images will be taken from 20 individuals with eating disorders 6 months after orthodontic treatment finished
Study NCT00227006 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral lifestyle/weight-loss intervention
Study NCT00227006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle/weight-loss intervention
Study NCT05744284 — intervention group
Intervention type: DEVICE
Intervention: electrocautery
Description: advantages reported in this study in terms of wound infections, healing time, postoperative pain and cosmetic results in association with economic gain for saving in the purchase of scalpels, represent a formidable motivation for the surgeons to abandon the scalpel in favors of diathermy
Study NCT00332280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT2003
Study NCT03181035 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (18)F-Fluoroazomycin arabinoside
Description: FAZA PET diagnostic testing
Study NCT03181035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimonidazole
Description: oral pimonidazole hypoxia labeling
Study NCT01484275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
Study NCT01484275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
Study NCT01681940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: ERT, i.v. infusions weekly
Study NCT03842397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kephalios Device 1
Description: The Kephalios Device 1 is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of the Kephalios Device 1 is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
Study NCT02485184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transjugular intrahepatic portosystemic shunt
Description: Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
Study NCT02485184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-selective beta blockers
Description: Non-selective beta blockers are the drugs for reducing the portal pressure.
Study NCT02485184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic therapy
Description: Endoscopic therapy includes the endoscopic variceal band ligation
Study NCT02485184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation
Description: Anticoagulation therapy includes heparin and warfarin.
Study NCT03106714 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR
Description: Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
Study NCT00851084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: administration: IV infusion
Study NCT00851084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: administration: IV infusion
Study NCT00851084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: administration: IV infusion
Study NCT00851084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: administration: IV infusion
Study NCT00851084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: administration: IV infusion
Study NCT00851084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: administration: IV infusion
Study NCT00851084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: administration: IV infusion
Study NCT03650023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chitosan Oligosaccharide (GO2KA1)
Description: Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
Study NCT03951688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental-Multi-modal exercise program
Description: Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
Study NCT03574935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: External Chinese medicine
Description: External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~1. Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~2. Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~3. Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome.
Study NCT03574935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: External Chinese medicine
Description: External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~1. Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~2. Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~3. Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome.
Study NCT03574935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: External Western medicine
Description: For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear).
Study NCT03574935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: External Western medicine
Description: For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear).
Study NCT01480141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 (Afatinib)
Description: Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
Study NCT03650023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White egg
Description: White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
Study NCT00730327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioEnterics® Intragastric Balloon
Description: Inflatable balloon inserted into the stomach.
Study NCT04070352 — intervention group
Intervention type: DRUG
Intervention: Fidaxomicin
Description: patients who are receiving fidaxomicin are enrolled into the study, blood is obtained for analysis, EMR and outcome data collected regarding their CDI
Study NCT02572258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional cookie
Study NCT00856479 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infuse Bone Morphogenic Protein (BMP) 2
Description: Infuse is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. Infuse may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention.
Study NCT00856479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iliac crest autograft
Description: A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
Study NCT01895816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coated tablet
Description: this supplement contains 700 mg of 8 natural herbals: Citrus \& ZINGIBER OFFICINALE \& Onion \& Ocimum basilicum \& Cinnamomum zelanicum \& Citrullus lanatus \& Citrullus vulgaris \& Daucus carota
Study NCT04467177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30% glucose
Description: Male neonates will receive 2 ml of 30% glucose two minutes prior to circumcision
Study NCT04467177 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Male neonates will receive 2 ml of sterile water two minutes prior to circumcision
Study NCT03096223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Description: IV administration
Study NCT00262080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ecallantide
Description: dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
Study NCT02833272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER Educational Brochure
Description: The EMPOWER educational brochure explains the risk of benzodiazepine and non-benzodiazepine sedative use to patients with a current prescription. The brochure also provides a tapering schedule if the patient chooses to discontinue taking the drug.
Study NCT01649180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
Study NCT00868569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE + folfox 4
Description: tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml~folfox4
Study NCT00868569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAC + folfox4
Description: tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4
Study NCT01987154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Marketed cow milk-based premature infant formula
Study NCT01987154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marketed extensively hydrolyzed casein infant formula
Study NCT04219137 — intervention group
Intervention type: GENETIC
Intervention: Molecular Profiling
Description: This is a correlative study collecting biosamples to evaluate genomic characteristics and treatment outcomes of gastroesophageal adenocarcinoma.
Study NCT03230396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamingum Sport
Description: Vitamin -supplemented chewing gum
Study NCT03230396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamingum Immunity
Description: Vitamin -supplemented chewing gum
Study NCT00262080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Saline (PBS),
Description: given as three 1mL subcutaneous injections.
Study NCT04895163 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy performed for acute appendicitis
Study NCT03105596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide plus DICE Regimen
Description: Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
Study NCT01319643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
Study NCT00808249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: 2 tablets taken twice a day for 28 days
Study NCT00808249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets taken twice a day for 28 days
Study NCT02145923 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral blood stem cell mobilisation and collection
Study NCT02145923 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: High-dose chemotherapy
Description: High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
Study NCT02145923 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bone marrow derived allogeneic MMSCs infusion
Study NCT02145923 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous peripheral blood stem cells infusion
Study NCT03009201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03009201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03009201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03009201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study NCT04606654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handgrip strength training without Blood flow restriction
Description: Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contract his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training.
Study NCT04606654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip strength training with Blood flow restriction
Description: Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contracts his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training. However, for one of the limbs the pneumatic blood pressure cuff will be placed on the upper arm, 4 cm proximal to the ante-cubital fossa. The decision which arm would receive the occlusion during training will be randomized to avoid a dominant or non-dominant hand bias. During experimental group training blood pressure cuff will be partially inflated (80 mmHg) to ensure venous occlusion. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training while the cuff remained inflated.
Study NCT01021072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABp1
Description: 0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
Study NCT03230396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control chewing gum. No vitamin content.
Study NCT00389597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Artificial Disc
Description: Cervical artificial disc mechanical device
Study NCT03592654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: infant telehelp
Description: Adapted from Early Start Denver Model (ESDM), a naturalistic developmental behavioral intervention
Study NCT05182190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White bread
Description: Toasted white bread
Study NCT05182190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black beans whole boiled
Description: Whole boiled black beans with spaghetti sauce
Study NCT05182190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Knife Mill pasta
Description: Black bean pasta (KM) with spaghetti sauce
Study NCT05182190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combo Flour Pasta
Description: Black bean pasta (Combo) with spaghetti sauce (medium protein flour)
Study NCT05182190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cyclone Flour Pasta
Description: Black bean pasta (Cyclone) with spaghetti sauce (low protein flour)
Study NCT01206075 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mozobil
Description: Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.